stent

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis

Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Glycemic Control and Coronary Stent Failure

Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>

Coronary Angioplasty with Sirolimus Eluting Stents

At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug coated balloons (DCB) have shown benefits in restenosis and small vessel de novo lesions.&nbsp; Intravascular ultrasound (IVUS) has been shown effective in left main PCI and complex procedures, even though there is little infomration on its use for<a href="https://solaci.org/en/2024/06/12/coronary-angioplasty-with-sirolimus-eluting-stents/" title="Read more" >...</a>

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by year 5 and 50% by year 10. BIOADAPTADOR RCT outcomes at 12 months have shown the safety and efficacy of DynamX Bioadaptor, establishing new reference parameters in arterial viability restoration. The aim of this study was to report<a href="https://solaci.org/en/2024/05/17/europcr-2024-2-year-outcomes-of-the-new-sirolimus-eluting-bioadaptor-vs-resolute-onyx-zotarolimus-elulting-stent/" title="Read more" >...</a>

EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?

The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary intervention (PCI) is superior to fluoroscopy guided PCI, using fractional flow reserve (FFR) after stenting. The secondary outcomes were procedural success (successful implantation, malposition, edge dissection or stent collapse) and major adverse cardiovascular events (MACE) at one year.<a href="https://solaci.org/en/2024/05/17/europcr-2024-doctors-lm-trial-cto-optimizes-stent-outcomes-in-left-main-disease/" title="Read more" >...</a>

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes

In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a prevalence between 5% and 10% after implantation of latest-generation drug-eluting stents (DES). Therapeutic recommendations for it include the implantation of a new DES and the use of drug-coated balloons (DCB). The rate of recurrent ISR ranges from 10%<a href="https://solaci.org/en/2024/04/29/treatment-of-recurrent-in-stent-restenosis-with-drug-eluting-stents-10-year-outcomes/" title="Read more" >...</a>

AGENT-IDE: Drug Coated Balloons for Instent Restenosis

Drug eluting stents (DES) have improved considerably over the years, reducing the initial indices of instent restenosis (ISR) by roughly 5-10% a year in USA. However, DES failure might lead to neointimal hyperplasia and neoatherosclerosis, which increases the chance of developing chronic and acute coronary syndromes.&nbsp; Drug coated balloons (DCB), which administer anti-proliferative agents with<a href="https://solaci.org/en/2024/03/21/agent-ide-drug-coated-balloons-for-instent-restenosis/" title="Read more" >...</a>

Survey on Hemodynamics Centers in Latin America &#8211; SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions within a single country. It is clear that the treatment of STEMI is still an unmet need in our region. SOLACI and the Stent &#8211; Save a Life! Initiative in Latin<a href="https://solaci.org/en/2024/03/12/survey-on-hemodynamics-centers-in-latin-america-solaci-stent-save-a-life-and-south-american-society-of-cardiology-initiative/" title="Read more" >...</a>

Network Meta-Analysis of Complementary Imaging (IVUS/OCT + Conventional Angiography) for Coronary Stenting

Complementary imaging allows for the identification of numerous scenarios not visible with conventional angiography (ICA), both for the assessment of differential diagnoses and the improvement of percutaneous coronary intervention (PCI) outcomes. Advantages include assessment of plaque characteristics, vessel plaque burden, stent edge dissection, vessel diameter, and correct apposition, among others. While intravascular ultrasound (IVUS) was<a href="https://solaci.org/en/2024/02/28/network-meta-analysis-of-complementary-imaging-ivus-oct-conventional-angiography-for-coronary-stenting/" title="Read more" >...</a>

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Recurrent Revascularization at 10 Years after Percutaneous Treatment of DES In-Stent Restenosis

In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and<a href="https://solaci.org/en/2024/02/22/recurrent-revascularization-at-10-years-after-percutaneous-treatment-of-des-in-stent-restenosis/" title="Read more" >...</a>

Top